糖尿病视网膜病变市场规模、份额、成长分析、按类型、按治疗方法、按诊断、按给药途径、按最终用户、按分销渠道、按地区 - 行业预测 2025-2032

2023 年糖尿病视网膜病变市场规模价值 95 亿美元，预计将从 2024 年的 101.6 亿美元增长到 2032 年的 173.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 6.9%。

由于糖尿病盛行率上升、人口老化以及糖尿病相关失明发病率增加，糖尿病市场预计将大幅成长。人们对糖尿病认识的提高和创新产品的推出进一步推动了这一趋势。糖尿病是由于胰臟无法产生胰岛素而引起的，这会导致血糖值升高，并可能损害视网膜的毛细血管，从而引发糖尿病视网膜病变。早期发现和介入、使用先进工具进行持续的自我监测以及改变生活方式对于降低这些风险至关重要。 CheckEye 基于人工智慧的糖尿病视网膜病变筛检平台等最新倡议凸显了加强早期检测的努力。此外，医疗支出的增加和预计到 2050 年老年人口将增加两倍对于塑造市场动态至关重要。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 专利分析
• 技术分析

糖尿病视网膜病变市场规模（按类型和复合年增长率）（2025-2032）

• 市场概况
• 非增生性糖尿病视网膜病变
• 增生性糖尿病视网膜病变

糖尿病视网膜病变市场规模（依治疗方法类型及复合年增长率）（2025-2032）

• 市场概况
• 药品
• 设备使用
• 外科手术
• 其他的

糖尿病视网膜病变市场规模（依诊断及复合年增长率）（2025-2032）

• 市场概况
• 造影萤光
• 光学同调断层扫描
• 其他的

糖尿病视网膜病变市场规模（依给药途径及复合年增长率） (2025-2032)

• 市场概况
• 口服
• 玻璃体内注射
• 玻璃体内植入
• 局部眼药水
• 雷射手术
• 其他的

糖尿病视网膜病变市场规模（依最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院
• 专科门诊
• 居家照护
• 其他的

糖尿病视网膜病变市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 零售药局
• 网路药局
• 其他的

糖尿病视网膜病变市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Bayer AG（Germany）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Oxurion NV（Belgium）
• Sirnaomics（China）
• Alimera Sciences（USA）
• Ampio Pharmaceuticals Inc.（USA）
• Kowa Company Ltd.（Japan）
• Genentech, Inc.（USA）
• Regeneron Pharmaceuticals Inc.（USA）
• Roche Holding AG（Switzerland）
• Allergan PLC（Ireland）
• Pfizer, Inc.（USA）
• Carl Zeiss Meditec AG（Germany）
• Topcon Corporation（Japan）
• Heidelberg Engineering GmbH（Germany）
• Optos PLC（UK）
• Canon Inc.（Japan）
• Nidek Co., Ltd.（Japan）
• Bausch+Lomb Incorporated（Canada）

结论和建议

Diabetic Retinopathy Market size was valued at USD 9.5 billion in 2023 and is poised to grow from USD 10.16 billion in 2024 to USD 17.32 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The diabetes market is poised for significant growth, driven by the escalating prevalence of diabetes, an aging population, and the increasing incidence of diabetes-related blindness. Heightened awareness about diabetes and the introduction of innovative products are further accelerating this trend. The condition arises from the pancreas's inability to produce insulin, leading to elevated blood sugar levels and potential damage to retinal blood capillaries, resulting in diabetic retinopathy. Early identification and intervention, continuous self-monitoring using advanced tools, and lifestyle changes are crucial for mitigating these risks. Recent initiatives, such as Check Eye's AI-powered platform for diabetic retinopathy screening, underscore efforts to enhance early detection. Additionally, rising healthcare spending and the projected tripling of the elderly population by 2050 will be vital in shaping market dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Diabetic Retinopathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Diabetic Retinopathy Market Segments Analysis

Global Diabetic Retinopathy Market is segmented by Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel and region. Based on Type, the market is segmented into Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. Based on Treatment, the market is segmented into Medication, Through Device, Surgery and Others. Based on Diagnosis, the market is segmented into Fluorescein Angiography, Optical Coherence Tomography and Others. Based on Route of Administration, the market is segmented into Oral, Intravitreal Injections, Intravitreal Implants, Topical Eye Drops, Laser Surgery, Others. Based on End-Users, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Diabetic Retinopathy Market

The diabetic retinopathy market is primarily driven by the rising global incidence of diabetes, which significantly heightens the prevalence of this common complication among diabetic patients. As more individuals are diagnosed with diabetes, the need for effective diagnostic tools and treatment solutions for diabetic retinopathy intensifies. This escalating diabetic population not only underscores the necessity for innovative therapies but also creates an expanding market for specialists and healthcare providers focused on managing and addressing the visual impairments associated with this condition. Consequently, the urgent demand for effective interventions stands as a vital propellant for the growth of the diabetic retinopathy market.

Restraints in the Diabetic Retinopathy Market

The diabetic retinopathy market faces several challenges that hinder its growth. A significant issue is the insufficient awareness among diabetic patients regarding the condition and the critical need for routine eye check-ups. Many individuals remain unaware of the risks associated with diabetic retinopathy, which can lead to severe vision impairment if not addressed promptly. Additionally, access to eye care services is often limited in remote or underserved regions, creating barriers to early detection and timely treatment. These factors collectively restrict the market's potential, underscoring the need for increased education and improved healthcare accessibility to mitigate these restraints.

Market Trends of the Diabetic Retinopathy Market

The diabetic retinopathy market is witnessing a notable trend towards early detection and intervention, driven by an increasing acknowledgment of the condition's progressive nature. Healthcare providers are investing in regular screening programs and community awareness campaigns to educate patients about the importance of timely diagnosis. Concurrently, advancements in imaging technologies, such as OCT and fundus photography, are enhancing the precision of early diagnosis. This proactive approach not only aims to reduce the incidence of severe vision loss but also to optimize treatment outcomes, thereby shaping the market dynamics and stimulating growth as both healthcare systems and patients prioritize preventive strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis
• Technology Analysis

Global Diabetic Retinopathy Market Size by Type & CAGR (2025-2032)

• Market Overview
• Non-Proliferative Diabetic Retinopathy
• Proliferative Diabetic Retinopathy

Global Diabetic Retinopathy Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Medication
• Through Device
• Surgery
• Others

Global Diabetic Retinopathy Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Fluorescein Angiography
• Optical Coherence Tomography
• Others

Global Diabetic Retinopathy Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravitreal Injections
• Intravitreal Implants
• Topical Eye Drops
• Laser Surgery
• Others

Global Diabetic Retinopathy Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Diabetic Retinopathy Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Diabetic Retinopathy Market Size & CAGR (2025-2032)

• North America (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Diagnosis, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sirnaomics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ampio Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kowa Company Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heidelberg Engineering GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optos PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nidek Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb Incorporated (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations